Company news

Janux Therapeutics, Inc. news in 2026

Janux Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

November 5, 2026

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

November 2, 2026

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

September 14, 2026

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

May 7, 2026

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

April 27, 2026

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

April 15, 2026

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

March 31, 2026

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 25, 2026

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

February 16, 2026

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

January 25, 2026

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

January 21, 2026

Decks in 2026